HRP20251484T1 - Pojačano doziranje tableta rukapariba - Google Patents

Pojačano doziranje tableta rukapariba

Info

Publication number
HRP20251484T1
HRP20251484T1 HRP20251484TT HRP20251484T HRP20251484T1 HR P20251484 T1 HRP20251484 T1 HR P20251484T1 HR P20251484T T HRP20251484T T HR P20251484TT HR P20251484 T HRP20251484 T HR P20251484T HR P20251484 T1 HRP20251484 T1 HR P20251484T1
Authority
HR
Croatia
Prior art keywords
tablet according
tablet
active pharmaceutical
pharmaceutical ingredient
range
Prior art date
Application number
HRP20251484TT
Other languages
English (en)
Croatian (hr)
Inventor
Jeffrey Etter
Original Assignee
Pharma& Schweiz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma& Schweiz Gmbh filed Critical Pharma& Schweiz Gmbh
Publication of HRP20251484T1 publication Critical patent/HRP20251484T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20251484TT 2014-08-22 2015-08-17 Pojačano doziranje tableta rukapariba HRP20251484T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US201562101739P 2015-01-09 2015-01-09
EP15833096.9A EP3182975B1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (1)

Publication Number Publication Date
HRP20251484T1 true HRP20251484T1 (hr) 2026-01-02

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251484TT HRP20251484T1 (hr) 2014-08-22 2015-08-17 Pojačano doziranje tableta rukapariba

Country Status (22)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR20170043597A (enExample)
CN (2) CN113209033A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
ES (1) ES3048688T3 (enExample)
FI (1) FI3182975T3 (enExample)
HR (1) HRP20251484T1 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
SI (1) SI3182975T1 (enExample)
WO (1) WO2016028689A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
KR20170043597A (ko) * 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
KR20190110579A (ko) 2017-01-24 2019-09-30 아시아 케미컬 인더스트리스 리미티드 루카파립 및 루카파립 염의 고체상 형태
JP2020512350A (ja) 2017-03-27 2020-04-23 テサロ, インコーポレイテッド ニラパリブ組成物
MY209708A (en) * 2017-09-26 2025-07-31 Tesaro Inc Niraparib formulations
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CA3146385A1 (en) 2019-07-10 2021-01-14 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
PT4143182T (pt) 2020-04-28 2025-03-13 Rhizen Pharmaceuticals Ag Novos compostos úteis como inibidores da poli(adp-ribose) polimerase (parp)
WO2022015557A1 (en) 2020-07-14 2022-01-20 Assia Chemical Industries Ltd Solid state forms of rucaparib salts
JP2023535744A (ja) 2020-07-29 2023-08-21 アラーガン ファーマシューティカルズ インターナショナル リミテッド 片頭痛の治療
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
CA3234080A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
US11738029B2 (en) * 2021-11-10 2023-08-29 Crititech, Inc. Rucaparib particles and uses thereof
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05006B1 (et) 1999-01-11 2008-04-15 Agouron Pharmaceuticals, Inc. Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid
BRPI0408996A (pt) 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
JP5466814B2 (ja) 2003-07-25 2014-04-09 カンサー リサーチ テクノロジー リミテッド 治療用化合物
DK1794163T3 (da) 2004-09-22 2010-04-12 Pfizer Fremgangsmåde til fremstilling af poly(ADP-ribose)polymeraseinhibitorer
EP1799685B1 (en) 2004-09-22 2012-03-28 Pfizer Inc. Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
RU2361592C2 (ru) 2004-09-22 2009-07-20 Пфайзер Инк. Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы
AU2009235426A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
BR112012019050B1 (pt) * 2010-02-12 2021-12-21 Pfizer Inc Sal anidro de forma a do s-camsilato de 8-fluoro-2-{metilamino)metil]fenil}-1,3,4,5-tetra- hidro-6hazepino[5,4,3cd]indol-6-ona, composição e uso do mesmo
HK1205028A1 (en) 2012-04-05 2015-12-11 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of atr kinase and combination therapies thereof
KR20170043597A (ko) * 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제

Also Published As

Publication number Publication date
US20180200260A1 (en) 2018-07-19
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
JP2020002149A (ja) 2020-01-09
ES3048688T3 (en) 2025-12-11
PT3182975T (pt) 2025-10-28
CA2955495A1 (en) 2016-02-25
US9987285B2 (en) 2018-06-05
SI3182975T1 (sl) 2025-12-31
KR20170043597A (ko) 2017-04-21
US10130636B2 (en) 2018-11-20
FI3182975T3 (fi) 2025-11-13
RU2017109139A (ru) 2018-09-24
LT3182975T (lt) 2025-11-25
CA2955495C (en) 2023-09-19
JP7127101B2 (ja) 2022-08-29
CN106794185A (zh) 2017-05-31
MX2017001540A (es) 2017-05-11
JP2017525712A (ja) 2017-09-07
CN113209033A (zh) 2021-08-06
JP2021038242A (ja) 2021-03-11
IL249946A0 (en) 2017-03-30
US20160051561A1 (en) 2016-02-25
WO2016028689A1 (en) 2016-02-25
JP6797980B2 (ja) 2020-12-09
SG11201700265VA (en) 2017-02-27
EP3182975A1 (en) 2017-06-28
BR112017000865A2 (pt) 2017-12-05
EP3182975B1 (en) 2025-10-01
US20190099430A1 (en) 2019-04-04
EP3182975A4 (en) 2018-04-18
AU2015305696A1 (en) 2017-02-02
RS67356B1 (sr) 2025-11-28
AU2019272064A1 (en) 2019-12-19
JP6574477B2 (ja) 2019-09-11
MX367260B (es) 2019-08-12
RU2705156C2 (ru) 2019-11-05
AU2019272064B2 (en) 2021-11-18
AU2015305696B2 (en) 2019-08-29
KR20230097211A (ko) 2023-06-30
KR102803917B1 (ko) 2025-05-07
RU2017109139A3 (enExample) 2019-03-06
NZ728392A (en) 2023-06-30

Similar Documents

Publication Publication Date Title
HRP20251484T1 (hr) Pojačano doziranje tableta rukapariba
JP2017525712A5 (enExample)
HRP20240231T1 (hr) Farmaceutske formulacije inhibitora brutonove tirozin kinaze
HRP20192065T1 (hr) Čvrsti oblici doziranja palbocikliba
UA116334C2 (uk) Тверді форми дозування бендамустину
HRP20250604T1 (hr) Formulacije tableta neratinib maleata
SG190448A1 (en) Rapidly dispersing granules, orally disintegrating tablets and methods
HRP20230616T1 (hr) Disperzivni pripravci
HRP20240564T1 (hr) Novi farmaceutski sastav
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
WO2016210003A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
MX2020002841A (es) Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
AR065096A1 (es) Preparacion solida
JP2018527305A5 (enExample)
AR074739A1 (es) Comprimidos de capecitabina de disgregacion rapida
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
HRP20161340T1 (hr) Formulacije darunavira
JP2016508516A5 (enExample)
HRP20192184T1 (hr) Optimizirana visokodozna tableta mesalazina
FI3509595T3 (fi) Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita
RU2019105711A (ru) Фармацевтическая композиция, содержащая помалидомид
RU2017111887A (ru) Фармацевтические композиции
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture